期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 64, 期 2, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01943-19
关键词
nontuberculous mycobacteria; NTM; rifamycin; mouse model; animal model
资金
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI132374, U19AI142731, R21AI145396]
There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus. Here, we report that rifabutin is as active as clarithromycin against M. abscessus K21 in NOD.CB17-Prkdc(scid)/NCrCrl mice. This suggests that rifabutin should be considered a repurposing candidate for patients with M. abscessus disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据